What is the recommended dose of acyclovir (antiviral medication) for the treatment of herpes simplex virus (HSV) meningitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Acyclovir Dosing for HSV Meningitis

The recommended dose of acyclovir for the treatment of herpes simplex virus (HSV) meningitis is 10 mg/kg intravenously every 8 hours for 14-21 days. 1

Dosing Recommendations

  • For adults with HSV meningitis, acyclovir should be administered at 10 mg/kg intravenously every 8 hours with normal renal function 1
  • Treatment duration should be 14-21 days to ensure adequate viral suppression and prevent relapse 1
  • Therapy should be initiated as soon as possible after symptom onset, as mortality decreases to 8% if treatment begins within 4 days of symptom onset 1
  • Dose adjustments are necessary for patients with impaired renal function 1

Clinical Considerations

  • Distinguishing between HSV meningitis and encephalitis is crucial, as encephalitis represents a more severe condition requiring aggressive treatment 2
  • HSV encephalitis has high mortality rates (up to 70%) without appropriate therapy, making prompt diagnosis and treatment essential 3
  • In neonates, higher-dose acyclovir (20 mg/kg intravenously every 8 hours for 21 days) has shown improved outcomes with decreased mortality to 5% 1, 4
  • For severe cases requiring hospitalization, intravenous therapy is mandatory rather than oral alternatives 1

Treatment Response Monitoring

  • Consider obtaining a repeat CSF specimen for PCR at the end of therapy in patients who have not had appropriate clinical response 1
  • If PCR remains positive for HSV at the end of treatment, antiviral therapy should be continued 1
  • Relapse of HSV infection has been reported after completion of acyclovir therapy, with rates as high as 5% 1

Special Populations

Immunocompromised Patients

  • Immunocompromised patients may require higher doses of antiviral medications 1
  • For HIV-infected patients with severe HSV disease, acyclovir 5 mg/kg IV every 8 hours is recommended 1
  • If acyclovir resistance is suspected (persistent lesions despite therapy), alternative treatments such as foscarnet (40 mg/kg IV every 8 hours) should be considered 1, 5

Recurrent HSV Meningitis

  • For recurrent HSV-2 meningitis (Mollaret's syndrome), valacyclovir 500 mg twice daily has not been shown to prevent recurrent episodes 6, 7
  • Treatment of acute episodes should follow the same guidelines as initial episodes 7

Potential Complications and Monitoring

  • Monitor renal function throughout treatment, as acyclovir can cause nephrotoxicity 1
  • Monitor complete blood count, as neutropenia can occur with high-dose acyclovir therapy 4
  • Approximately 21% of patients receiving high-dose acyclovir may experience neutropenia, which typically resolves during or after completion of therapy 4

Alternative Administration Methods

  • Continuous infusion of acyclovir has been explored as an alternative to thrice-daily dosing, particularly for outpatient therapy, though this is not standard practice 8

The evidence strongly supports intravenous acyclovir at 10 mg/kg every 8 hours for 14-21 days as the standard of care for HSV meningitis, with treatment initiated as early as possible to improve outcomes 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Incubation Period and Treatment of Herpes Meningitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tratamiento para la Reactivación de Herpes Tipo 2 Después de un Episodio de Meningoencefalitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Feasibility of Continuous Infusions of Acyclovir.

The Pediatric infectious disease journal, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.